See the DrugPatentWatch profile for Lacosamide
What is Lacosamide API?
Lacosamide is an active pharmaceutical ingredient (API) used in the formulation of medications for treating partial-onset seizures in adults and children. It works by selectively enhancing the slow inactivation of voltage-gated sodium channels, which helps to stabilize hyperexcitable neuronal membranes [1]. Lacosamide is available as an oral tablet, an oral solution, and an intravenous solution [2].
How does Lacosamide work?
Lacosamide's primary mechanism of action involves the slow inactivation of voltage-gated sodium channels. Unlike some other anti-epileptic drugs that target fast inactivation, lacosamide's action on slow inactivation is thought to contribute to its efficacy in seizure control without causing rapid dose-dependent neurological side effects [3].
When does Lacosamide patent exclusivity expire?
The patent landscape for lacosamide is complex, with various patents covering different aspects of the drug, including its synthesis, formulations, and uses. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceutical products, including lacosamide [4]. Generally, patent expiry dates determine when generic versions of a drug can enter the market.
Who manufactures Lacosamide API?
Several pharmaceutical companies are involved in the manufacturing of lacosamide API and its finished dosage forms. These include originator companies and generic manufacturers. Information on specific manufacturers and their products can often be found through pharmaceutical databases and regulatory filings [4].
What are the potential side effects of Lacosamide?
Common side effects associated with lacosamide use include dizziness, nausea, vomiting, headache, and somnolence. Less common but serious side effects can include depression, suicidal behavior, and allergic reactions [2]. Patients should discuss any concerns with their healthcare provider.
Can generic versions of Lacosamide be made before patent expiry?
Generally, generic versions of a drug cannot be legally manufactured and marketed until relevant patents have expired or have been successfully challenged. The Hatch-Waxman Act in the United States provides a framework for generic drug approval, which includes considerations for patent protection. Companies may attempt to challenge existing patents or seek to market generics after the expiration of primary patents [4].
What is the difference between Lacosamide and other anti-epileptic drugs?
Lacosamide differentiates itself from other anti-epileptic drugs primarily through its mechanism of action, focusing on the slow inactivation of sodium channels. This targeted approach may offer a different efficacy and tolerability profile compared to drugs with broader mechanisms, such as those affecting GABAergic neurotransmission or other ion channels [3]. The choice of an anti-epileptic drug depends on individual patient needs, seizure type, and response to treatment.
---
Sources:
1. https://www.drugpatentwatch.com/drug/lacosamide
2. https://www.drugs.com/lacosamide.html
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773021/
4. https://www.drugpatentwatch.com/